First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use

NICE

2 June 2023 - NICE’s final draft guidance recommends mavacamten (Camzyos, Bristol-Myers Squibb) as an add-on to standard care that aims to control symptoms of the disease.

Clinical trial evidence suggests that mavacamten and standard care is more effective than standard care alone, and that it may avoid or postpone the need for invasive surgery.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder